Erik Engebretsen

Develops and sells pharmaceuticals and medical devices

Engages in shipping and investment activities

MV's venture capital investment strategy focuses on firms displaying high-growth potential in international markets. Their investment objective is to create long-term capital growth through an investment philosophy which promotes concepts of corporate sustainability. They look for investments where they can add value based on their core business development competencies. They target investment sectors within clean technology. MV also evaluates other investment criteria such as established firms with sector-experienced managers in key positions, products that have clear utility, viable business model, documented experience on the international market, firms facing a development phase that will improve the company's market position and value, competitively sustainable activity or product, and sound company ethics. MV's investment level ranges from NOK 4 million to 15 million. They take direct equity or provide convertible loans. They take minority positions from 10% to 49%. As active investment partners, they take Board seats on their portfolio firms. Their investment time frame generally ranges from three to seven years. Their exit strategy is influenced by the level of value creation. They exit though trade sales and buyouts.

Provides pharmaceutical products and services